Molecular Formula | CH7Cl2NaO7P2 |
Molar Mass | 286.9 |
Solubility | Soluble in Water (up to at least 10 mg/ml) |
Appearance | White solid |
Color | White |
Merck | 14,2371 |
Storage Condition | 2-8°C |
Stability | Stable for 1 year from date of purchase as supplied. Solutions in distilled water may be stored at -20°C for up to 3 months. |
In vitro study | Clodronate disodium tetrahydrate, a first-generation bisphosphonate, significantly attenuates neuropathic and inflammatory pain unrelated to bone abnormalities via inhibition of VNUT, a key molecule for the initiation of purinergic chemical transmission . Clodronate disodium tetrahydrate is an allosteric modulator of VNUT Cl - dependence . Clodronate disodium tetrahydrate acts as antiresorptive in osteoporosis. |
RTECS | SZ7640700 |
overview | clodronate disodium is an organic compound, developed by Leiras pharmaceutical factory in the Netherlands and listed in 1986. it mainly inhibits bone resorption, prevents hydroxyapatite dissolution and inhibits osteoclast activity. |
use | clodronate disodium (tetrahydrate) can treat bone metastases and relieve pain, and has the best analgesic effect on bone metastases of breast cancer, with an effective rate of 90%. |
biological activity | Clodronate disodium tetrahydrate (Disodium clodronate tetrahydrate) is the first generation bisphosphonate, which has anti-osteoporosis, anti-inflammatory and analgesic effects. Clodronate disodium tetrahydrate is a selective, efficient, reversible, Cl-competitive vesicular nucleotide transporter (VNUT) blocker with an IC50 value of 15.6 nM. Clodronate disodium tetrahydrate can inhibit neuronal release of vesicular ATP and relieve chronic neuropathic pain and inflammatory pain. |
target | vesicular ATP release |
Animal Model: | C57BL/6 mice (22-30 g) |
Dosage: | 10 mg/kg |
Administration: | Intravenous injection |
Result: | Attenuated carrageenan- or complete Freund’s adjuvant (CFA)-evoked inflammatory pain. |